ライフサイエンスコーパス: fluticasone

1 HLMCs were present, but this was reversed by fluticasone.

2 any effect on suppression of inflammation by fluticasone.

3 cantly lower doses and with lower costs than fluticasone.

4 95% CI, 0.73-0.93) than patients started on fluticasone.

5 nt prescribed HFA-beclomethasone rather than fluticasone.

6 100 microg twice daily) to receive continued fluticasone (100 microg twice daily) (169 patients), mon

7 h asthma that was well controlled by inhaled fluticasone (100 microg twice daily) to receive continue

8 t (5 or 10 mg each night) (166 patients), or fluticasone (100 microg) plus salmeterol (50 microg) eac

9 y TNFalpha alone was completely abrogated by fluticasone (100 nM), dexamethasone (1 microM), or budes

10 meterol-low-dose fluticasone vs. medium-dose fluticasone, 49% vs. 28% [P = 0.003]; salmeterol-medium-

11 eterol-medium-dose fluticasone vs. high-dose fluticasone, 49% vs. 31% [P = 0.02]).

12 pregnancy (n = 1231; 79.9% budesonide, 17.6% fluticasone, 5.4% beclomethasone, and 0.9% other or unsp

13 rol (50 mug) plus the inhaled glucocorticoid fluticasone (500 mug) twice daily.

14 onsiveness to methacholine, received inhaled fluticasone (880 microg daily) for 12 weeks.

15 t this hypothesis, we studied the effects of fluticasone, AC, or both on AMos of C57BL/6 mice in vitr

16 Patients receiving fluticasone achieved a significantly higher rate of clin

17 e hydrofluoroalkane (HFA)-beclomethasone and fluticasone administered through a pressurized metered-d

18 1), salmeterol (73 mL, 46-101, p<0.0001), or fluticasone alone (95 mL, 67-122, p<0.0001).

19 eceive either fluticasone with salmeterol or fluticasone alone for 26 weeks.

20 ve fluticasone propionate plus salmeterol or fluticasone alone for 26 weeks.

21 ard ratio with fluticasone-salmeterol versus fluticasone alone was 1.28 (95% confidence interval [CI]

22 Noninferiority of fluticasone-salmeterol to fluticasone alone was defined as an upper boundary of th

23 ated event that was similar to the risk with fluticasone alone.

24 a-related events than did those who received fluticasone alone.

25 e fluticasone-salmeterol group and 21 in the fluticasone-alone group had a serious asthma-related eve

26 sone-salmeterol group and 309 (10.0%) in the fluticasone-alone group had a severe asthma exacerbation

27 Fluticasone, an inhaled steroid commonly used to treat a

28 with fluticasone/salmeterol (64% vs 23% 2.5x fluticasone and 13% fluticasone/montelukast in the Best

29 and in 46% of the children with doubling the fluticasone and adding salmeterol (P = 0.99).

30 In vitro fluticasone and budesonide reduced MR1 surface expressio

31 reated with topical corticosteroids, such as fluticasone and budesonide, or dietary strategies, such

32 nd CCL5 by TNF-alpha was insensitive to both fluticasone and dexamethasone in ASM cells from severe a

33 in 46% of the children with quintupling the fluticasone and in 46% of the children with doubling the

34 ing their first ICS as HFA-beclomethasone or fluticasone and matched on baseline demographic characte

35 interferon (IFN) beta was administered with fluticasone and rhinovirus 1B in both groups of mice.

36 asal recombinant IFN beta (10(4) units) with fluticasone and rhinovirus 1B led to upregulation of int

37 P-10 compared with control mice treated with fluticasone and rhinovirus alone and improved viral clea

38 All participants received high-dose fluticasone and salmeterol and continued other pre-study

39 study evaluates the contribution of inhaled fluticasone and salmeterol, alone or combined, to the re

40 d additively and synergistically enhanced by fluticasone and salmeterol, respectively.

41 ha-treated HASM cells, which was enhanced by fluticasone and salmeterol.

42 nd additively enhanced by the glucocorticoid fluticasone and the beta(2)-agonist salmeterol, whereas

43 ilanterol); a control arm (not given inhaled fluticasone); and pre-randomisation measurements of bloo

44 and 336 patients randomized to montelukast, fluticasone, and placebo, respectively.

45 15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induc

46 from the run-in period of open-label inhaled fluticasone, and the treatment periods for subjects rand

47 Combined activity of salmeterol and fluticasone at equimolar concentrations had no effect on

48 upper gastrointestinal tract manifestations; fluticasone, azithromycin, and montelukast should be use

49 We found that prednisone, fluticasone, budesonide, and progesterone each increased

50 ntrolled with the use of twice-daily inhaled fluticasone can be switched to once-daily fluticasone pl

51 e dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered dose inhaler [MDI], flunisolide-

52 Halcinonide, fluticasone, clobetasol, and fluocinonide provide an unp

53 tified four FDA-approved drugs, halcinonide, fluticasone, clobetasol, and fluocinonide, as Smo agonis

54 a2-agonist/inhaled corticosteroid salmeterol/fluticasone combination 50/500 mug in patients with one

55 nced by suppressed BAL neutrophil numbers in fluticasone compared with control mice (0.021 x 10(5) [0

56 salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of

57 orticosteroid was reduced, or the cumulative fluticasone dose during the trial.

58 alfway through the trial, and the cumulative fluticasone dose during the trial.

59 lomethasone doses were lower (P < .001) than fluticasone doses (median, 320 mug/d [interquartile rang

60 iamcinolone-CFC), only the placebo group and fluticasone DPI did not demonstrate a significant dose-r

61 [CFC], budesonide dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered dose inhaler [M

62 s whether an exhalation delivery system with fluticasone (EDS-FLU) capable of high/deep drug depositi

63 ects randomized to (1) continued twice daily fluticasone (F), (2) once daily fluticasone plus salmete

64 More importantly, fluticasone failed to induce GRE-dependent gene transcri

65 ium was significantly superior to salmeterol/fluticasone for the prevention of exacerbations (all sev

66 nophilic esophagitis (EoE) include swallowed fluticasone from a multi-dose inhaler (MDI) or oral visc

67 95% CI 0.75-1.14]) with similar findings for fluticasone furoate (0.90 [0.72-1.11]) and vilanterol (0

68 , vilanterol (25 mug), or the combination of fluticasone furoate (100 mug) and vilanterol (25 mug).

69 locks to receive once daily inhaled placebo, fluticasone furoate (100 mug), vilanterol (25 mug), or t

70 ear [95% CI 1-15]) with similar findings for fluticasone furoate (difference 8 mL per year [95% CI 1-

71 the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) and long-acting beta(2) -agonis

72 Fluticasone furoate (FF) is a novel, once-daily ICS asth

73 Genotyping and imputation was performed in fluticasone furoate (FF) or fluticasone propionate-treat

74 tructive Pulmonary Disease Treatment) trial, fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol

75 ontrolled trial, once-daily inhaled placebo, fluticasone furoate (FF; 100 mug), vilanterol (VI; 25 mu

76 ere pretreated with either cetirizine 10 mg, fluticasone furoate 27.5 mug, or placebo to alleviate th

77 randomly assigned to initiate treatment with fluticasone furoate and vilanterol (n=2114) or usual car

78 V1) and the increased risk of pneumonia with fluticasone furoate and vilanterol compared with vilante

79 ightened cardiovascular risk, treatment with fluticasone furoate and vilanterol did not affect mortal

80 hose on usual care (977 [71%] of 1373 in the fluticasone furoate and vilanterol group vs 784 [56%] of

81 f a once-daily treatment regimen of combined fluticasone furoate and vilanterol improved asthma contr

82 Across all doses of inhaled corticosteroids, fluticasone furoate and vilanterol reduced exacerbations

83 er for patients who initiated treatment with fluticasone furoate and vilanterol than for those on usu

84 fractures were reported more frequently with fluticasone furoate and vilanterol than with vilanterol

85 , a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with a

86 We hypothesised that fluticasone furoate and vilanterol would prevent more ex

87 patients (605 assigned to usual care, 602 to fluticasone furoate and vilanterol) had a baseline ACT s

88 ms (fluticasone propionate and salmeterol or fluticasone furoate and vilanterol); a control arm (not

89 nts from baseline in patients initiated with fluticasone furoate and vilanterol, compared with 2.8 po

90 Reductions in exacerbations with fluticasone furoate and vilanterol, compared with vilant

91 COPD to a once-daily inhaled combination of fluticasone furoate at a dose of 100 mug and vilanterol

92 tion; 4111 in the placebo group, 4135 in the fluticasone furoate group, 4118 in the vilanterol group,

93 18% in the combination group, and 17% in the fluticasone furoate group, and 17% in the vilanterol gro

94 roup, 6% in the combination group, 5% in the fluticasone furoate group, and 4% in the vilanterol grou

95 vilanterol plus 50 mug, 100 mug, or 200 mug fluticasone furoate in patients with moderate-to-severe

96 ng-term effect of the inhaled corticosteroid fluticasone furoate on exacerbation frequency.

97 ined with either 50 mug, 100 mug, or 200 mug fluticasone furoate once daily.

98 Addition of fluticasone furoate to vilanterol was associated with a

99 led combination of either 100 mug or 200 mug fluticasone furoate with 25 mug vilanterol or optimised

100 Fluticasone furoate, alone or in combination with vilant

101 a combined treatment of the corticosteroid, fluticasone furoate, and the long-acting beta agonist, v

102 ative reduction; p=0.137) or the components (fluticasone furoate, HR 0.91 [0.77-1.08]; p=0.284; vilan

103 itude of benefit of regimens containing ICS (fluticasone furoate-umeclidinium-vilanterol n=4151 and f

104 ng once-daily single-inhaler triple therapy (fluticasone furoate-umeclidinium-vilanterol) with dual i

105 mug and vilanterol at a dose of 25 mug (the fluticasone furoate-vilanterol group) or to usual care (

106 s serious adverse events of pneumonia in the fluticasone furoate-vilanterol group.

107 e furoate-umeclidinium-vilanterol n=4151 and fluticasone furoate-vilanterol n=4134) in reducing rates

108 inium-vilanterol) with dual inhaled therapy (fluticasone furoate-vilanterol or umeclidinium-vilantero

109 (95% confidence interval, 1.1 to 15.2), with fluticasone furoate-vilanterol therapy than with usual c

110 uL or more; the corresponding rate ratio for fluticasone furoate-vilanterol versus umeclidinium-vilan

111 al pro-apoptotic effect of dexamethasone and fluticasone furoate.

112 ction in all-cause mortality (ACM) risk with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)

113 aring 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 mug/62.5

114 led corticosteroid/long-acting beta2-agonist fluticasone furoate/vilanterol 100/25 mug or placebo (7-

115 bation rate was noted between the 200/25 mug fluticasone furoate/vilanterol group and the vilanterol

116 ight deaths from pneumonia were noted in the fluticasone furoate/vilanterol groups compared with none

117 e and severe exacerbations were noted in all fluticasone furoate/vilanterol groups than in the vilant

118 e and severe exacerbations were noted in all fluticasone furoate/vilanterol groups than in the vilant

119 Fluticasone furoate/vilanterol safety profile was simila

120 P < 0.001) reduction in residual volume with fluticasone furoate/vilanterol versus placebo.

121 -glycopyrronium group than in the salmeterol-fluticasone group (0.98 vs. 1.19; rate ratio, 0.83; 95%

122 -glycopyrronium group than in the salmeterol-fluticasone group (3.59 vs. 4.03; rate ratio, 0.89; 95%

123 e first exacerbation than did the salmeterol-fluticasone group (71 days [95% CI, 60 to 82] vs. 51 day

124 -glycopyrronium group than in the salmeterol-fluticasone group (hazard ratio, 0.78; 95% CI, 0.70 to 0

125 copyrronium group and 4.8% in the salmeterol-fluticasone group (P=0.02).

126 Fewer patients in the fluticasone group withdrew from the study due to lung-re

127 e combination-therapy group and 18.3% in the fluticasone group) than in the placebo group (12.3%, P<0

128 opyrronium group, and 1682 to the salmeterol-fluticasone group.

129 5% in the salmeterol group, and 16.0% in the fluticasone group.

130 Fluticasone group: n=84, median age 14.6 yr, mean (SD) F

131 indacaterol/glycopyrronium versus salmeterol/fluticasone (hazard ratio, 0.76; 95% CI, 0.56-1.03; P =

132 Patients treated with fluticasone improved significantly more rapidly (median

133 fter therapy with the inhaled corticosteroid fluticasone in independent cohorts.

134 bo-controlled trial of pre-emptive high-dose fluticasone in preschoolers with URTI-induced asthma.

135 bo-controlled trial of pre-emptive high-dose fluticasone in preschoolers with virus-induced asthma.

136 pyrronium was more effective than salmeterol-fluticasone in preventing COPD exacerbations in patients

137 feriority but also superiority to salmeterol-fluticasone in reducing the annual rate of all COPD exac

138 to continued triple therapy or withdrawal of fluticasone in three steps over a 12-week period.

139 By contrast, fluticasone increased MUC5AC proteins (158.2 arbitrary u

140 KCa3.1 channel blockade also restored fluticasone-induced GC receptor-alpha phosphorylation at

141 Fluticasone-induced GRalpha nuclear translocation, phosp

142 om hospital patients were given a salmeterol/fluticasone inhaler with an INCA device attached.

143 Despite increasing viral loads, fluticasone inhibited rhinovirus-induced airway inflamma

144 ice daily plus a placebo inhaler (n = 56) or fluticasone MDI (880 mug) twice daily plus a placebo slu

145 initial treatment of EoE with either OVB or fluticasone MDI produced a significant decrease in esoph

146 nificantly lower for HFA-beclomethasone than fluticasone (mean, $1869 [95% CI, $1727-$2032] vs $2259

147 Fluticasone/salmeterol and fluticasone monotherapy decreased peripheral airway smoo

148 Fluticasone/salmeterol and fluticasone monotherapy equally reverse peripheral airwa

149 meterol (64% vs 23% 2.5x fluticasone and 13% fluticasone/montelukast in the Best ADd-on Therapy Givin

150 iver homogenate reference sample, except for fluticasone, nicardipine, and sorafenib which suffer fro

151 indacaterol-glycopyrronium versus salmeterol-fluticasone on the rate of COPD exacerbations was indepe

152 the fluticasone-salmeterol group than in the fluticasone-only group (hazard ratio, 0.79; 95% CI, 0.70

153 pared with 597 of 5845 patients (10%) in the fluticasone-only group (P<0.001).

154 no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthma-related intubati

155 e asthma exacerbations than did those in the fluticasone-only group.

156 ol group and 38 events in 33 patients in the fluticasone-only group.

157 ere defined as daily therapy with 500 mug of fluticasone or greater with or without a long-acting bet

158 received fluticasone; they then took either fluticasone or placebo for 6 mo.

159 0% of patients assigned to receive continued fluticasone or switched to treatment with fluticasone pl

160 a step-up to double to quintuple the dose of fluticasone, or both.

161 45% (montelukast, P < .05 vs placebo), 49% (fluticasone, P < .001 vs placebo), and 39% (placebo); th

162 one twice daily (ICS step-up), 100 microg of fluticasone plus 50 microg of a long-acting beta-agonist

163 Mice treated with fluticasone plus AC before infection with viable pneumoc

164 ment to the lungs at 48 h postinfection, and fluticasone plus AC less markedly reduced in vitro media

165 Fluticasone plus AC significantly reduced in vitro AMo k

166 Fluticasone plus AC significantly reduced TLR4-stimulate

167 twice daily fluticasone (F), (2) once daily fluticasone plus salmeterol (F + S), or (3) once daily o

168 se budesonide plus formoterol, or fixed-dose fluticasone plus salmeterol for 6 months.

169 se budesonide plus formoterol and fixed-dose fluticasone plus salmeterol for 7 months.

170 ed fluticasone or switched to treatment with fluticasone plus salmeterol had treatment failure, as co

171 ed fluticasone can be switched to once-daily fluticasone plus salmeterol without increased rates of t

172 thasone, methylprednisolone, budesonide, and fluticasone, potentiated TGF-beta signaling by the Acvrl

173 Fluticasone produced a wide spectrum of changes in the b

174 Patients receiving fluticasone propionate <=500 mcg/day or equivalent were

175 C57BL/6 mice were intranasally dosed with fluticasone propionate (1 mg/kg) or vehicle (dimethyl su

176 ma and treated them for 30 days with inhaled fluticasone propionate (1,760 microg/day) followed by a

177 ng patients receiving medications containing fluticasone propionate (19.6% in the combination-therapy

178 twice daily), and the inhaled glucocorticoid fluticasone propionate (500 mug twice daily) during a 6-

179 percentage difference, -15%; P = .0115), and fluticasone propionate (absolute difference, -1.64; perc

180 ve asthma predictive index to treatment with fluticasone propionate (at a dose of 88 mug twice daily)

181 uiring daily therapy with 500 mug or more of fluticasone propionate (FLU) with or without a long-acti

182 FF 50 mcg dosed in the evening, twice-daily fluticasone propionate (FP) 100 mcg or placebo.

183 lind, crossover study evaluating twice daily fluticasone propionate (FP) 100 mug, FP 500 mug and plac

184 crossover study and inhaled single doses of fluticasone propionate (FP) 100 mug, FP 500 mug, salmete

185 e efficacy and safety of high-dose swallowed fluticasone propionate (FP) and dose reduction in patien

186 We evaluated the effects of fluticasone propionate (FP) and of salmeterol (SM), on t

187 ce were studied to determine whether inhaled fluticasone propionate (FP) could attenuate airway infla

188 we determined the effects of salmeterol and fluticasone propionate (FP) in seven steroid-naive patie

189 aimed to determine the efficacy of swallowed fluticasone propionate (FP) in the treatment of eosinoph

190 ddition, the effects of IL-4, IFN-gamma, and fluticasone propionate (FP) on nasal epithelial cells we

191 antiinflammatory agents montelukast (ML) and fluticasone propionate (FP) on Qaw in 12 patients with m

192 the efficacy of MP-AzeFlu (Dymista((R)) ) vs fluticasone propionate (FP), (both 1 spray/nostril bid),

193 hages, matured in the presence or absence of fluticasone propionate (FP), and their ability to initia

194 H3N2 and either or not treated with inhaled fluticasone propionate (FP), systemic corticosteroids (P

195 estigated the effects of importin-7 siRNA on fluticasone propionate (FP)-induced GR nuclear localizat

196 age I to II) before and after treatment with fluticasone propionate (FP)/salmeterol (SM) (50/500, 4 w

197 Two puffs (total dose, 200 microgram) of fluticasone propionate (n = 47) or placebo nasal spray (

198 allergy were treated with run-in medication (fluticasone propionate 100 mug bid) during 2 weeks befor

199 d, double-blind, controlled study of inhaled fluticasone propionate 100 mug twice daily in young chil

200 re not under control by 3 months, open-label fluticasone propionate 100 mug twice daily was added to

201 lind study to placebo (n = 73) or salmeterol/fluticasone propionate 50/500 microg (n = 67) twice dail

202 29-02 (a novel formulation of azelastine and fluticasone propionate [FP]) in patients with moderate-t

203 The mortality rate for salmeterol alone or fluticasone propionate alone did not differ significantl

204 inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years.

205 gate the effects of common asthma treatments fluticasone propionate and beta(2) agonists salmeterol a

206 owders containing the inhaled corticosteroid fluticasone propionate and long-acting beta2-agonist sal

207 COPD that had: inhaled corticosteroid arms (fluticasone propionate and salmeterol or fluticasone fur

208 confirming the presence of peaks related to fluticasone propionate at 1743, 1661, and 1700 cm(-1), s

209 aring salmeterol at a dose of 50 microg plus fluticasone propionate at a dose of 500 microg twice dai

210 tiotropium, 100 mug salmeterol, and 1000 mug fluticasone propionate daily for 6 weeks and were then r

211 0.3 +/- 15.2 years; ACT score, 14.6 +/- 3.8; fluticasone propionate dose, 718 +/- 470 mug).

212 The early use of inhaled fluticasone propionate for wheezing in preschool childre

213 The combination of salmeterol and fluticasone propionate has a broad spectrum of antiinfla

214 BI 671800 (50, 200, and 400 mg twice daily), fluticasone propionate nasal spray (200 mug once daily),

215 this study was to assess effects of inhaled fluticasone propionate on rhinovirus infection in vivo,

216 0 to 500 mug, and >500 mug, respectively, of fluticasone propionate or equivalent for adults with ast

217 ly dose," which is defined as 200-250 mug of fluticasone propionate or equivalent, representing the d

218 core >/=1.5) after uptitration to 1000 mug/d fluticasone propionate or greater were randomized to 3 o

219 ukast (our primary hypothesis) or once-daily fluticasone propionate plus salmeterol (our secondary hy

220 xacerbations in the previous year to receive fluticasone propionate plus salmeterol or fluticasone al

221 treatment with the synthetic glucocorticoid fluticasone propionate prevented chitosan-induced barrie

222 The potent topical glucocorticoid fluticasone propionate significantly suppressed dsRNA-de

223 tes, both 10 mg/d montelukast and 250 mug of fluticasone propionate twice daily significantly increas

224 evaluates 10 mg/d montelukast and 250 mug of fluticasone propionate twice daily, each compared with p

225 over the benchmark inhaled corticosteroid 3 (fluticasone propionate) and prolonged the inhibition of

226 ly (fluticasone propionate), INCS on demand (fluticasone propionate) or oral antihistamine on demand

227 nolone acetonide, clobetasol propionate, and fluticasone propionate) predominantly accounted for GR a

228 ta2-agonist (salmeterol) and corticosteroid (fluticasone propionate) will reduce inflammation.

229 A (salmeterol) to an inhaled glucocorticoid (fluticasone propionate), a step-up to double to quintupl

230 Patients received either INCS daily (fluticasone propionate), INCS on demand (fluticasone pro

231 bo (n = 96) for 48 weeks and maintained with fluticasone propionate, 176 mug/d (6-11 years old), or 2

232 oth TH1 and TH2 cytokines, was additive with fluticasone propionate, and inhibited cytokine release f

233 the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination in c

234 the results after adjustment for open-label fluticasone propionate, nor between the two groups in th

235 and primary cultures], roflumilast enhanced fluticasone propionate-induced GRE-dependent transcripti

236 was performed in fluticasone furoate (FF) or fluticasone propionate-treated patients with asthma from

237 combination with an inhaled glucocorticoid, fluticasone propionate.

238 Long-term efficacy and safety of Fluticasone propionate/formoterol fumarate hydrate (FP/F

239 Inhaler monitors recorded fluticasone propionate/salmeterol adherence (covertly fo

240 We found that the GC fluticasone rapidly and dose-dependently increased AC up

241 Fluticasone rapidly suppressed AMo expression of SIRPalp

242 superior or similar benefits over salmeterol/fluticasone regardless of blood eosinophil levels in pat

243 atics and PP5 knockdown using siRNA restored fluticasone repressive action on chemokine production an

244 l blockade led to a significant reduction of fluticasone-resistant CX3CL1, CCL5, and CCL11 gene and p

245 relapse in 14 randomized controlled trials (fluticasone: risk ratio, 1.31; 95% CI, 1.02-1.68; tacrol

246 ME (Effect of Indacaterol Glycopyrronium vs. Fluticasone Salmeterol on COPD Exacerbations) study used

247 LAME (Effect of Indacaterol Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, whi

248 e to added salmeterol than to an increase in fluticasone (salmeterol-low-dose fluticasone vs. medium-

249 ic horses (6 horses/group) were treated with fluticasone, salmeterol, fluticasone/salmeterol, or with

250 to 2.27), which showed the noninferiority of fluticasone-salmeterol (P=0.006).

251 Among the 6208 patients, 27 patients in the fluticasone-salmeterol group and 21 in the fluticasone-a

252 A total of 265 patients (8.5%) in the fluticasone-salmeterol group and 309 (10.0%) in the flut

253 events, with 36 events in 34 patients in the fluticasone-salmeterol group and 38 events in 33 patient

254 ere asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-onl

255 io for a serious asthma-related event in the fluticasone-salmeterol group was 1.03 (95% confidence in

256 ccurring in 480 of 5834 patients (8%) in the fluticasone-salmeterol group, as compared with 597 of 58

257 Patients receiving fluticasone-salmeterol had fewer severe asthma exacerbat

258 Noninferiority of fluticasone-salmeterol to fluticasone alone was defined

259 ere hospitalizations); the hazard ratio with fluticasone-salmeterol versus fluticasone alone was 1.28

260 lung function cluster had best response with fluticasone/salmeterol (64% vs 23% 2.5x fluticasone and

261 e advertised during the period examined: (1) fluticasone/salmeterol (Advair), (2) mometasone furoate

262 ve effects in patients with asthma receiving fluticasone/salmeterol (FP/SM) combination and FP alone.

263 She is on fluticasone/salmeterol 500/50 mug one inhalation twice d

264 Fluticasone/salmeterol and fluticasone monotherapy decre

265 Fluticasone/salmeterol and fluticasone monotherapy equal

266 In conclusion, this study shows that fluticasone/salmeterol combination decreases extracellul

267 Only fluticasone/salmeterol decreased bronchoalveolar neutrop

268 In central airways, fluticasone/salmeterol reversed extracellular matrix rem

269 ) were treated with fluticasone, salmeterol, fluticasone/salmeterol, or with antigen avoidance for 12

270 l subgroups, and at no cutoff was salmeterol/fluticasone superior to indacaterol/glycopyrronium.

271 was higher in patients receiving salmeterol/fluticasone than indacaterol/glycopyrronium in both the

272 NCS on-demand group used on average 61% less fluticasone than patients in the INCS daily group during

273 In children receiving fluticasone, the ADYC score was significantly lower vers

274 he 2-mo run-in period, all patients received fluticasone; they then took either fluticasone or placeb

275 The addition of fluticasone to xylometazoline and antimicrobial therapy

276 eterol (50 mug twice a day) and doubling the fluticasone (to 100 mug twice a day), a superior respons

277 When quintupling the dose of fluticasone (to 250 mug twice a day) was compared with a

278 type I and III IFNs in the airways (for the fluticasone-treated group compared with controls: mean I

279 d IL-1beta-induced IL-6 production; however, fluticasone treatment caused a reduction of IL-6 protein

280 urfactant protein D inhibited AC uptake, and fluticasone treatment rapidly reversed this inhibition.

281 At 24 h post infection, fluticasone treatment suppressed rhinovirus induction of

282 Our findings suggest that fluticasone treatment suppresses rhinovirus-induced airw

283 mild atopic asthma before and after inhaled fluticasone treatment, 18 atopic subjects without asthma

284 airway hyperresponsiveness after 6 weeks of fluticasone treatment.

285 specific microbiota members were seen after fluticasone treatment.

286 in random order for 16 weeks: 250 microg of fluticasone twice daily (ICS step-up), 100 microg of flu

287 (n=374), 50 microg salmeterol and 500 microg fluticasone twice daily (n=358), or placebo (n=361) for

288 g salmeterol twice daily (n=372), 500 microg fluticasone twice daily (n=374), 50 microg salmeterol an

289 with persistent asthma receiving 250 mug of fluticasone twice daily for 2 weeks were randomized to r

290 twice daily (LABA step-up), or 100 microg of fluticasone twice daily plus 5 or 10 mg of a leukotriene

291 trolled asthma while receiving 100 microg of fluticasone twice daily, to receive each of three blinde

292 95% confidence interval) of 0.59 (0.23-1.48) fluticasone versus placebo.

293 fidence interval) of 1.07 (0.68 to 1.70) for fluticasone versus placebo.

294 significantly lower in children treated with fluticasone versus those treated with placebo (mean diff

295 vs. 28% [P = 0.003]; salmeterol-medium-dose fluticasone vs. high-dose fluticasone, 49% vs. 31% [P =

296 increase in fluticasone (salmeterol-low-dose fluticasone vs. medium-dose fluticasone, 49% vs. 28% [P

297 salmeterol in a fixed-dose combination with fluticasone was associated with the risk of a serious as

298 ebo); the difference between montelukast and fluticasone was not significant (P = .14).

299 dian value) tended to show more benefit with fluticasone, whereas those with a smoking history of >11

300 We compared mice treated with fluticasone with controls at various timepoints after in

301 stent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26